Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PAM | P19021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910307 | 0.83 | TSHR (0.67) | TSHRTDP1ALDH1A1GAAPKM | |
| SCHEMBL18195547 | 0.83 | TSHR (0.57) | TSHRTDP1ALDH1A1GAAPKM | |
| SCHEMBL28550279 | 0.83 | TSHR (0.67) | TSHRTDP1ALDH1A1GAAPKM | |
| Allyl Hexanoate SCHEMBL29527701 | 0.83 | TSHR (0.71) | TSHRTDP1ALDH1A1LMNAMAPT | |
| SCHEMBL2492438 | 0.82 | TSHR (0.60) | TSHRTDP1ALDH1A1GAAPKM | |
| SCHEMBL153651 | 0.80 | TSHR (0.77) | TSHRTDP1ALDH1A1GAACYP1A2 | |
| SCHEMBL28931215 | 0.80 | TSHR (0.61) | TSHRTDP1ALDH1A1GAAPKM | |
| SCHEMBL1226647 | 0.80 | LTA4H (0.53) | TSHRLTA4HTDP1ALDH1A1CYP1A2 | |
| SCHEMBL28249376 | 0.79 | TSHR (0.70) | TSHRTDP1ALDH1A1GAAPKM | |
| SCHEMBL11131759 | 0.78 | TSHR (0.74) | TSHRTDP1ALDH1A1GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009912-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2005-01-13 | — | — | US | disclosed |
| EP-1463713-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1458671-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1423411-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003057661-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003045898-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003006489-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009912-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A3, SLC1A1 | TSHR 1142/4885LTA4H 3098/4885TDP1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.